drugset / Trial / NCT00262236

Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension

NCT00262236

Phase 3 Completed 693 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.

Timeline

Start
2005-11
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg
Subject Aliskiren Small molecule 300 mg